Background: STE029 is a novel anticancer drug which consists of 3-hydroxy-3-methylglutarylcoenzyme A reductase inhibitor and novel cancer cell membrane targeting molecular. This study aimed to investigate the effect and mechanism of STE029 on overcoming the EGFR-TKI resistance in NSCLC. Method: CCK8 test was used to test the cell viability and survival rate of EGFR mutated PC9 cell (Gefitinib sensitive), PC9/BB4 cell (acquired Gefitinib resistant), and EGFR wild type A549 cell after treatment of STE029, Gefitinib or combination of both. Edu test was applied to detect changes in cell cycle and Hoechst 33258 was applied to detect apoptosis rate in treatment groups. We examined the activity of EGFR/PI3K/Akt, cell cycle and apoptosis signal pathways. In vivo, nude mice were exposed to STE029, Gefitinib and STE029+Gefitinib for 5 weeks, tumor volume was measured, tumor weight was obtained on the last day. P value less than 0.05 would be considered statistically significant. Results: PC9 Cells was highly sensitive to Gefitinib , while PC9/BB4 and A549 cell showed significant resistance to Gefitinib treatment, the IC50 of Gefitinib in PC9, PC9/BB4 and A549 cell was 0.12±0.113umol/L, 11.41±0.014 umol/L and 14.39±0.016 umol/L, respectively; The IC50 of STE029 in PC9, PC9/ BB4 and A549 cell was 2.48±0.028umol/L, 7.80±0.058umol/L, 8.27±0.016umol/L, respectively; STE029+Gefitinib treatment could significantly decrease the IC50 of Gefitinib in PC9, PC9/BB4 and A549 cells( p<0.05, respectively). In PC9 and PC9/BB4 cells, STE029+G-efitinib can block cell cycle and inhibit cell proliferation, while there was no significant difference in apoptosis rate among three drug intervention groups; However, Apoptosis rate was increased in STE029+Gefitinib group in A549 cell, while no significance detected in cell proliferation. In PC9 and PC9/BB4 cells, the combination of STE029 and Gefitinib could down regulate p-EGFR, p-Akt, p-Cyclin D1 and Cyclin D1,up-regulate the expression of GSK-3b,and the expression of cleaved caspase-8, caspase-8, cleaved caspase-9, caspase-9 showed no difference among groups; In A549 cells, the combination of STE029 and Gefitinib could down regulate p-Akt, up-regulate cleaved caspase-8 and cleaved caspase-9. In vivo, the combination of STE029 and Gefitinib effectively controlled tumor development and progression compared to STE029 alone or Gefitinib alone with significant difference (P<0.05) in PC9 and PC9/BB4 xenografted tumor. Conclusion: STE029 could sensitizer Gefitinib in inhibiting EGFR/PI3K/Akt pathway, blocking the tumor cell cycle and proliferation and inducing apoptosis through caspase-8 and caspase-9 dependent pathway. STE029 deserves further investigations in overcoming EGFR-TKI resistance in lung cancer. Background: This phase I study aimed to establish the feasible dose of Apatinib in combination with pemetrexed plus carboplatin as first-line therapy for EGFR-negative stage IV non-squamous nonsmall-cell lung cancer (NSCLC). Method: Using a 3+3 dose-reduction design, patients received oral Apatinib at four dose levels: 750 mg qd, 500 mg qd, 500 mg/day 2 weeks on/1 week off schedule (schedule 2/1) or 250mg qd. Pemetrexed (500 mg/m2) plus carboplatin (AUG¼5) was administered every 3 weeks. The feasible dose was determined based on cycle 1 dose-limiting toxicities (DLT); other assessments included safety and antitumor activity according to response evaluation criteria in solid tumors. Results: A total of 12 patients were enrolled and cycle 1 DLTs were observed in two patients at 750 mg qd treatment (both Grade 3 hypertension), two patients at 500 mg qd (Grade 3 hypertension and Grade 3 hand-foot syndrome), and only one of six patients at 500 mg/day schedule 2/1 (Grade 3 hypertension). The most frequently drug-related adverse events were hematological toxicity, hypertension, hand-foot syndrome and hepatic transaminases elevation. Partial response was observed in 4 patients of 11 evaluable patients (ORR 36.4%), and 6 patients exhibited stable disease (DCR 90.9%). Conclusion: In patients with advanced non-squamous NSCLC, the feasible dose of Apatinib given with standard-dose pemetrexed and carboplatin was 500 mg/day schedule 2/1. The schedule was generally well tolerated and demonstrated promising clinical benefit in NSCLC. Keywords: Apatinib, phase I, Non-Small Cell Lung Cancer
P068 The Geriatric Nutritional Risk Index Predicts the Overall Survival in Geriatric Patients with Metastatic Lung Adenocarcinoma
M. Tang, L. Li Oncology Department, Beijing Hospital, National Center of Gerontology, China, Beijing/CN Background: Metastatic lung adenocarcinoma patients have poor prognosis. Many factors are associated with the prognosis of lung cancer patients, including nutrition status. Geriatric nutrition risk index (GNRI) is a simplified, objective screening parameter for nutrition risk in geriatric patients. The aim of this study was to assess the prognostic value of pretreatment GNRI in geriatric patients with metastatic lung adenocarcinoma, which has not been reported before. Method: The clinical and pathological data of 144 consecutive geriatric patients with metastatic lung adenocarcinoma between January 2011 and May 2017 were retrospectively analyzed. The pretreatment GNRI was calculated as follows: GNRI¼1.489Âpretreatment serum albumin concentration (g/L)+41.7Âpretreatment body weight(kg)/ideal body weight(kg); ideal body weight(kg)¼Height-100-[(Height-150)/4](for men) or Height-100-[(Height-150)/2.5](for women); when pretreatment body weight exceeded ideal body weight, pretreatment body weight/ideal body weight was set to 1. The receiver operating characteristic (ROC) curve was used to determine the best cutoff value of GNRI for predicting OS. The KaplaneMeier method with Log-rank test was used to estimate survival curves. Univariate and multivariate Cox regression were used to identify variables associated with overall survival (OS) in the whole cohort, EGFR wildtype subgroup and EGFR mutation subgroup, respectively. Results: According to ROC results, the patients were divided into malnutrition risk group (MNRG) (GNRI 97, N¼75) and normal nutrition group(NNG) (GNRI>97, N¼69). Low GNRI value was significantly associated with older age (P¼0.002) and high ECOG score (P¼0.037). In Kaplan-Meier analysis of OS, NNG had significantly longer OS compared to the MNRG (1-year OS, 85.6%vs.54.7%, P<0.0001) in the whole cohort. In EGFR wildtype subgroup (N¼60), the normal nutrition patients had significantly longer OS compared to the malnutrition risk patients (1-year OS, 77.5%vs.36.4%, P<0.0001). In the EGFR mutation group (N¼84), the normal nutrition group had longer OS than the malnutrition risk patients, but did not reach significance (1-year OS, 96.6%vs.80.6%, P¼0.099). Univariate and multivariate Cox regression analyses showed that low GNRI value (P¼0.019), liver metastases(P<0.0001), EGFR mutation status(P<0.0001) were independent prognostic factors of OS. Further analysis showed that low GNRI value (P¼0.025), liver metastases (P<0.0001), ECOG (P¼0.008) were independent prognostic factors of OS in the EGFR wildtype
